New hope for MS muscle stiffness: phase 3 drug trial launches
NCT ID NCT05179577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an extended-release tablet called arbaclofen to see if it safely reduces muscle stiffness (spasticity) in people with multiple sclerosis. About 442 adults aged 18 to 65 with MS-related spasticity will receive either the drug or a placebo. The goal is to measure changes in muscle tightness and overall function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?